Clinical trial

Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection: A Randomized Controlled Double-Blind Study

Name
19-01299
Description
The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
Trial arms
Trial start
2020-12-01
Estimated PCD
2022-08-12
Trial end
2022-08-23
Status
Terminated
Phase
Early phase I
Treatment
Barbotage
Administered as per standard of care
Arms:
Barbotage Injection, Barbotage with Cortisone Injection
Dexamethasone
4 mg of dexamethasone
Arms:
Barbotage with Cortisone Injection
Other names:
cortisone
Size
4
Primary endpoint
Visual Analog Scale (VAS) Score at Visit 1
Visit 1 (Day 0)
VAS Score at Visit 2
Visit 2 (Week 6)
VAS Score at Visit 3
Visit 3 (Month 3)
VAS Score at Visit 4
Visit 4 (Month 6)
QuickDASH Score at Visit 1
Visit 1 (Day 0)
QuickDASH Score at Visit 4
Visit 4 (Month 6)
American Shoulder and Elbow Surgeons (ASES) Index Score at Visit 1
Visit 1 (Day 0)
ASES Index Score at Visit 4
Visit 4 (Month 6)
Radiographic Size of Calcium Deposit at Visit 1
Visit 1 (Day 0)
Radiographic Size of Calcium Deposit at Visit 4
Visit 4 (Month 6)
Eligibility criteria
Inclusion Criteria: * Must be at least 18 years of age and younger than 90 years of age * Diagnosed with calcific tendonitis and ruled out other shoulder-related pathologies * Failed 1st line therapy (physical therapy and cortisone injection) * Intention to receive barbotage with cortisone as standard of care * 3 or more months of shoulder pain * Finding of one or more calcifications ≥5 mm in size on either sonogram or radiograph, located on the supraspinatus tendon * Positive Hawkin's test or Neer's sign for impingement Exclusion Criteria: * Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.) * Osteoarthritis of the glenohumeral joint of the affected shoulder * Previous surgery or barbotage to the affected shoulder * History of prior allergic/hypersensitivity reactions related to the study medication * Shoulder instability, glenohumeral arthritis, AC pathology, inflammatory arthropathy, fibromyalgia, frozen shoulder or cervical radiculopathy * Sub-acromial injection with a corticosteroid or treatment by ESWT during the last 3 months before inclusion * Younger than 18 years of age or older than 90 * Any patient considered a vulnerable subject
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 4, 'type': 'ACTUAL'}}
Updated at
2024-01-05

1 organization

2 products

1 indication

Organization
NYU Langone Health
Product
Barbotage